Exploration of Identification and Prognostic Analysis of a Novel Immune-Related lncRNA Pair Signature and Immune Landscape in Esophageal Adenocarcinoma: A New Method Based on “Continuous Learning” Model

Abstract

With the rapid development of information technology, many medical systems have emerged one after another with the support of continuous learning. A method of medical data privacy protection and resource utilization based on continuous learning is proposed to initialize the depth model of specific medical tasks. The depth model includes feature sampling model, data review model and task expression model, Finally, the depth model is trained according to the data from n institutions in turn. This method can overcome the obstacles of data sharing. The intelligent medical system of medical knowledge sharing will greatly improve the level of existing medical technology. An increasing body of evidence suggests that long non-coding RNAs (lncRNAs) participate in various physiological processes and pathological diseases. Esophageal adenocarcinoma develops rapidly with poor prognosis and high mortality in the near and long term. Immunotargeted therapy is a research hotspot. However, it is necessary to explore the immunomodulatory molecules of esophageal adenocarcinoma and analyze their relationship with clinicopathological characteristics and prognosis. We aimed to construct a robust immune-related lncRNA signature associated with survival outcomes in esophageal adenocarcinoma. We identified an immune-related lncRNA pairs signature with prognostic value from The Cancer Genome Atlas. Differentially expressed immune-related lncRNAs (DEirlncRNAs) were identified and paired, followed by prognostic assessment using univariate Cox regression analysis. We used least absolute shrinkage and selection operator penalized Cox analysis for constructing a risk score prognostic model and drew receiver operating characteristic (ROC) curves to predict overall survival. Then, we evaluated our signature in several settings: chemotherapy, tumor-infiltrating immune cells, and immune-mediated gene expression. In total, 339 DEirlncRNA pairs were identified, 11 of which were involved in the risk score prognostic signature. The area under ROC curves representing the predictive effect for 1-, 2-, and 3-year survival rates were 0.942, 0.987, and 0.977, respectively. The risk score model was confirmed as an independent prognostic factor and was significantly superior to clinicopathological characteristics. Correlation analyses showed disparities in drug sensitivity, tumor-infiltrating immune cells, and immune-related gene expression. We identified a novel prognostic immune-related lncRNA pair signature for esophageal adenocarcinoma. The risk score-based groups displayed different immune statuses, drug sensitivity, and immune-mediated gene expression. These findings may offer insights into the prognostic evaluation of esophageal adenocarcinoma and may provide a basis for creating personalized treatment plans.